Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

Abstract Background The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. Methods We retrospectively analyzed data from breast cancer patients who bega...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Fan Yang, Xiang Huang, Chunxiao Sun, Jianbin Li, Biyun Wang, Min Yan, Feng Jin, Haibo Wang, Jin Zhang, Peifen Fu, Tianyu Zeng, Jian Wang, Wei Li, Yongfei Li, Mengzhu Yang, Jun Li, Hao Wu, Ziyi Fu, Yongmei Yin, Zefei Jiang
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2020-03-01
Edice:BMC Cancer
Témata:
Lapatinib
Trastuzumab
Resistance
Breast cancer
On-line přístup:http://link.springer.com/article/10.1186/s12885-020-6639-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky